Kalvista Pharmaceuticals Inc (OQ:KALV)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: Building 200, 1 Kendall Sq Ste 2203
CAMBRIDGE MA 02139-1562
Tel: N/A
Website: www.kalvista.com
IR: See website
Key People
Thomas Andrew Crockett
Chief Executive Officer, Director
Benjamin L. Palleiko
Chief Financial Officer, Chief Business Officer
Andreas Maetzel
Senior Vice President, Medical
Edward P. Feener
Chief Scientific Officer
Christopher M. Yea
Chief Development Officer
Business Overview
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Financial Overview
For the fiscal year ended 30 April 2019, Kalvista Pharmaceuticals Inc revenues increased 92% to $16.1M. Net loss increased 32% to $20.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$1.53 to -$1.38.
Employees: 45 as of Apr 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $204.41M as of Apr 30, 2019
Annual revenue (TTM): $16.13M as of Apr 30, 2019
EBITDA (TTM): -$29.44M as of Apr 30, 2019
Net annual income (TTM): -$20.82M as of Apr 30, 2019
Free cash flow (TTM): -$37.45M as of Apr 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,388,298 as of Jul 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization